'
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Five Countries Contributing to Clinical Trials in Europe 10
Top Countries Contributing to Clinical Trials in North America 11
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 12
Top Five Countries Contributing to Clinical Trials in Central and South America 13
Clinical Trials by G7 Countries: Proportion of Macular Degeneration to Ophthalmology Clinical Trials 14
Clinical Trials by Phase in G7 Countries 15
Clinical Trials in G7 Countries by Trial Status 16
Clinical Trials by E7 Countries: Proportion of Macular Degeneration to Ophthalmology Clinical Trials 17
Clinical Trials by Phase in E7 Countries 18
Clinical Trials in E7 Countries by Trial Status 19
Clinical Trials by Phase 20
In Progress Trials by Phase 21
Clinical Trials by Trial Status 22
Clinical Trials by End Point Status 23
Subjects Recruited Over a Period of Time 24
Clinical Trials by Sponsor Type 25
Prominent Sponsors 26
Top Companies Participating in Macular Degeneration Therapeutics Clinical Trials 27
Prominent Drugs 29
Clinical Trial Profile Snapshots 30
Appendix 530
Abbreviations 530
Definitions 530
Research Methodology 531
Secondary Research 531
About GlobalData 532
Contact Us 532
Disclaimer 532
Source 533
List of Tables
Macular Degeneration Therapeutics, Global, Clinical Trials by Region, 2016* 6
Macular Degeneration Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Macular Degeneration Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
Macular Degeneration Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 9
Macular Degeneration Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 10
Macular Degeneration Therapeutics Clinical Trials, North America, Top Countries, 2016* 11
Macular Degeneration Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2016* 12
Macular Degeneration Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2016* 13
Proportion of Macular Degeneration to Ophthalmology Clinical Trials, G7 Countries (%), 2016* 14
Macular Degeneration Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
Macular Degeneration Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
Proportion of Macular Degeneration to Ophthalmology Clinical Trials, E7 Countries (%), 2016* 17
Macular Degeneration Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18
Macular Degeneration Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19
Macular Degeneration Therapeutics, Global, Clinical Trials by Phase, 2016* 20
Macular Degeneration Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 21
Macular Degeneration Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22
Macular Degeneration Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23
Macular Degeneration Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24
Macular Degeneration Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 25
Macular Degeneration Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26
Macular Degeneration Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 28
Macular Degeneration Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 29
List of Figures
Macular Degeneration Therapeutics, Global, Clinical Trials by Region (%), 2016* 6
Macular Degeneration Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Macular Degeneration Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
Macular Degeneration Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 9
Macular Degeneration Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 10
Macular Degeneration Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 11
Macular Degeneration Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2016* 12
Macular Degeneration Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2016* 13
Proportion of Macular Degeneration to Ophthalmology Clinical Trials, G7 Countries (%), 2016* 14
Macular Degeneration Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
Macular Degeneration Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
Proportion of Macular Degeneration to Ophthalmology Clinical Trials, E7 Countries (%), 2016* 17
Macular Degeneration Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18
Macular Degeneration Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19
Macular Degeneration Therapeutics, Global, Clinical Trials by Phase (%), 2016* 20
Macular Degeneration Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 21
Macular Degeneration Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22
Macular Degeneration Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23
Macular Degeneration Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24
Macular Degeneration Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 25
Macular Degeneration Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26
Macular Degeneration Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 27
Macular Degeneration Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 29
GlobalData Methodology 531